Back to search

Peptide record

TPDB91972

CA-MA-P CA-MA2 Antibacterial Anticancer Antifungal Antiparasitic Toxicity standard
18 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB91972
CA-MA-P CA-MA2
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF
standard
No
A 18-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
KWKLFKKIPKFLHSAKKF-NH2
Physicochemical Analysis
C115H180N28O20
RNDCEQGMTYV
K
2274.87
11.29
8
0
8
+7
1.63
-0.639
70.56
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
5500
241.77
1
Residue Composition
number
1
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
1
H
1
I
2
L
7
K
0
M
3
F
1
P
1
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 1 L: 2 K: 7 M: 0 F: 3 P: 1 S: 1 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
18
C115H180N28O20
2274.87
11.29
+7
1.63
-0.639
Amidation
L
Linear
Free
Antibacterial
Ceropin A Ceropin-Magainin hybrid peptides
Evidence Records 7 records
Evidence 1 Activity

Activity

IC50
IC50=20 µM
Anticancer
20 µM

Target

Breast Cancer
MDA-MB-361
Breast

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2001

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=20 µM
Anticancer
20 µM

Target

Blood Cancer
Jurkat
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2001
Evidence 3 Activity

Activity

IC50
IC50=25 µM
Anticancer
25 µM

Target

Leukemia Cancer
K-562
Blood

Assay & Model

MTT/MTS assay
48-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2001
Evidence 4 Activity

Activity

IC50
IC50=35.1 µM
Anticancer
35.1 µM

Target

Leukemia Cancer
K-562
Blood

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2000
Evidence 5 Activity

Activity

IC50
IC50=25 µM
Anticancer
25 µM

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2000
Evidence 6 Activity

Activity

IC50
IC50=20 µM
Anticancer
20 µM

Target

Blood Cancer
Jurkat
Blood

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2000
Evidence 7 Activity

Activity

IC50
IC50=28 µM
Anticancer
28 µM

Target

Breast Cancer
MDA-MB-361
Breast

Assay & Model

MTT/MTS assay
72-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2000